Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...

Beth Mole, Ars Technica The First Crispr Treatment Is Making Its Way to Patients It’s been a year since the gene-editing ...

The launch of Casgevy, CRISPR Therapeutics' gene therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), represents a significant milestone for the company.

The launch of Casgevy, CRISPR Therapeutics' gene therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), represents a significant milestone for the company. As of the ...

A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

Detailed price information for Archer Aviation Inc (ACHR-N) from The Globe and Mail including charting and trades.